首页 > 市场调查报告书 > 医疗设备

市场调查报告书

商品编码

1784776

全球四重特异性抗体的临床试验，专利技术，治疗方法，市场机会的洞察(2025年)

Global Tetraspecific Antibodies Clinical Trials, Proprietary Technologies, Therapeutic Approaches & Market Opportunity Insight 2025

出版日期: 2025年08月01日 | 出版商:

KuicK Research | 英文 100 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球四特异抗体临床试验、专有技术、治疗方法和市场机会 (2025) 报告结果和要点

首个四特异抗体获准上市：预计于 2029 年实现
目前临床开发及未来商业化展望
中国和美国在四特异抗体临床开发领域占据主导地位
公司、国家、适应症和阶段划分的四特异抗体临床试验洞察
四特异抗体开发技术平台洞察
四特异抗体联合策略

对四特异抗体的需求及本报告的意义

对抗复杂疾病对新型疗法的需求日益增长癌症、自体免疫疾病和传染病等疾病的日益严重，促使多靶点抗体的开发显着增加。这些抗体旨在同时结合四种不同的抗原，提供比传统单特异性抗体更有效、更广泛用途的治疗方案。

四特异性抗体尤其可以克服目前治疗方法的不足，例如无法同时作用于多种致病途径。透过单一治疗药物标靶多个关键分子，四特异性抗体有可能最大限度地提高治疗效果，同时降低抗药性风险。同时针对多个标靶的能力使得抗体在癌症和自体免疫疾病中特别重要，因为这些疾病的进程由许多相互关联的因素所驱动。

本报告对四特异性抗体的现状进行了深入分析，并及时提供了临床开发、技术平台、关键参与者和未来前景的见解。对于製药和生物技术行业的利益相关者，无论是学术研究人员、医生还是商业决策者，本报告都是了解四特异性抗体疗法快速变化的最新情况的必读资料。

本报告包含临床试验洞察

四特异性抗体仍处于早期开发阶段，临床试验为此新兴领域的进展提供了重要数据。目前，正在进行临床试验的四特异性抗体不足10种，其中大多数处于早期阶段。

本报告分析了这些临床试验的各个阶段，重点介绍了正在研究的主要适应症，并确定了参与的申办者。报告也提供了这些试验开展地区的数据。本报告中的详细资讯不仅提供了最新数据，还清楚地展现了该药物研发管线的发展势头，这对于寻求四特异性抗体疗法潜在突破的投资者来说是一个重要指标。

基于技术平台的四特异性抗体的开创性开发

四特异性抗体的设计和开发依赖先进的技术平台。此类平台的一个例子是 Molecular Partners 的 DARPin（设计锚蛋白重复蛋白）技术，在设计高度可自订的多特异性抗体方面展现出巨大潜力。 DARPin 旨在同时结合多种抗原，提供更高的灵活性和特异性。 DARPin 平台的主要优势包括延长的半衰期、肿瘤靶向免疫活化以及针对突变的分层防御，使其在不断变化的疾病环境中更加稳健。透过同时靶向多种抗原，基于 DARPin 的四特异性抗体即使在其中一个标靶发生突变时也能保持活性，从而提供更持久的治疗反应。

本报告详细概述了用于开发四特异性抗体候选物的平台。此外，也讨论了其他一些尚未充分探索、具有未来四特异性开发潜力的平台。这些平台为扩展四特异性功能以更有效地治疗多方面疾病提供了巨大的潜力。

许多领先的生物技术和製药公司正在大力投资四特异性研发，每家公司都拥有各自的专业知识和技术平台。 Molecular Partners、Innate Pharma 和 ModeX Therapeutics 等公司是四特异性抗体疗法开发的先驱，专注于癌症、自体免疫和发炎性疾病。

本报告概述了这些关键公司、它们目前的研发活动以及它们各自追求的治疗标靶。透过研究这些公司的活动，利害关係人可以深入了解四特异性抗体开发的竞争动态以及这个令人兴奋的治疗领域的领导者和创新者。

总而言之，从治疗角度来看，四特异性抗体前景广阔。这项技术前景光明，后续研究将增强这些抗体的疗效、安全性和传递能力。这些抗体的新适应症正在扩展到自体免疫疾病和传染病等疾病。随着对个人化和多标靶治疗的日益关注，四特异性抗体很可能在精准医疗方法中发挥重要作用。

本报告全面探讨了下一代四特异性抗体开发的趋势、机会和挑战。随着精准医疗、生物标记发现和新型生物技术平台的不断发展，四特异性抗体有望在多种疾病的治疗中发挥关键作用。本报告全面回顾了临床试验、尖端技术平台和领先的行业利益相关者，对于希望在这一快速发展的领域保持领先地位的人士而言，它无疑是一份不可或缺的工具，能够清晰地洞察四特异性抗体的现状和未来发展方向。

First Tetraspecific Antibody Approval & Availability Expected Approval By 2029
Current Clinical Development Scenario & Future Commercialization Outlook
China & USA dominating tetraspecific Clinical Developmental Landscape
Tetraspecific Antibodies Clinical Trials Insight by Company, Country, Indication & Phase
Insight On Technology Platforms For Development Of Tetraspecific Antibodies
Combination Strategies For Tetraspecific Antibodies

Need for Tetraspecific Antibodies & Why This Report?

The escalating need for novel therapies in the battle against complex diseases such as cancer, autoimmune diseases, and infectious diseases has triggered a massive increase in the development of multi targeted antibodies, and perhaps one of the most promising advances in this area is the emergence of tetraspecific antibodies. These antibodies are designed to bind to four different antigens at once, providing a stronger, more versatile solution for treatment than conventional mono-specific antibodies.

In particular, tetraspecific antibodies can overcome the shortcomings of current therapies, including their inability to engage in more than one disease causing pathway at the same time. By targeting multiple critical molecules in a single therapeutic agent, tetraspecific antibodies have the possibility to maximize the effectiveness of treatments while maybe lowering the risk of drug resistance. The capacity to target multiple targets simultaneously renders them especially valuable in cancer and autoimmune disease, where the disease process is caused by numerous interlinked factors.

This report presents a deep dive analysis of the state of tetraspecific antibodies today, providing timely insights into their clinical development, technology platforms, leading players, and future prospect. For pharmaceutical and biotechnology industry stakeholders alike, whether they are academic researchers, physicians, or commercial decision-makers, this report is a must-read for remaining up-to-date on the fast-moving field of tetraspecific antibody drugs.

Clinical Trials Insight Included In Report

Tetraspecific antibodies are still in the early stages of development, and clinical trials are providing important data on the progress of this emerging field. Currently, fewer than 10 tetraspecific antibodies are being investigated in clinical trials, most of which are in the early phases.

This report examines the different phases of these trials, highlights the major indications being explored, and identifies the sponsors involved. It also provides data on the geographic locations where these trials are being conducted. The detailed information presented here not only offers current data but also provides a clear view of the pipeline's momentum, which serves as a key indicator for investors looking to identify potential breakthroughs in tetraspecific antibody treatments.

Technology Platforms: Pioneering Developments In Tetraspecific Antibodies

Tetraspecific antibodies rely on pioneering technology platforms to design and develop them. An example of such a platform is the DARPin (Designed Ankyrin Repeat Proteins) technology from Molecular Partners, which has demonstrated tremendous potential in designing highly customizable, multi-specific antibodies. DARPins are designed to bind to multiple antigens in parallel, providing better flexibility and specificity. Some of the primary advantages of the DARPin platform are extended half-life, tumor directed immune activation, and multi-layered protection against mutations, thereby making them more robust in shifting disease environments. By targeting multiple antigens simultaneously, DARPin-based tetraspecific antibodies are able to retain activity even when one target has mutated, thereby providing more sustained therapeutic responses.

This report gives a detailed overview of the platforms utilized in the development of tetraspecific antibody candidates. It also discusses other upcoming platforms that have potential for future tetraspecific antibody development but are yet to be fully explored. These hold significant promise for broadening the functionality of tetraspecific antibodies for the treatment of multifaceted diseases in a more efficient manner.

Key Companies Involved In R&D of Tetraspecific Antibodies

A number of top biotechnology and pharmaceutical firms are heavily investing in the research and development of tetraspecific antibodies, each with individual expertise and technology platforms. Firms such as Molecular Partners, Innate Pharma, and ModeX Therapeutics are pioneering the development of tetraspecific antibody treatments, with a strong emphasis on oncology and autoimmune and inflammatory disorders.

The report gives a view of such major players, their current R&D activities, and the respective therapeutic targets being pursued. By reviewing the activity of these firms, stakeholders can have some great insight into the competitive dynamics of tetraspecific antibody development, the leaders and innovators of this exciting therapeutic space.

Report Highlighting Future Direction Of Tetraspecific Antibodies Segment

In summary, tetraspecific antibodies are incredibly promising from a therapeutic perspective. The prospects of this technology are bright in the future, with subsequent studies set to enhance the efficacy, safety, and delivery of these antibodies. The new indications for these antibodies extend into conditions like autoimmune diseases and infectious diseases. With increasing focus on personalized and multi-target therapies, tetraspecific antibodies are set to be an important part of precision medicine approaches in the years ahead.

This report delivers a comprehensive look into the trends, opportunities, and challenges of the next generation of tetraspecific antibody development. As precision medicine, biomarker discovery, and new biotechnology platforms continue to evolve, tetraspecific antibodies will play a vital role in the treatment of multifaceted diseases. Providing a comprehensive review of clinical trials, cutting-edge technology platforms, and leading industry stakeholders, the report is an essential tool for those who want to remain at the forefront in this fast evolving space, offering a crystal-clear vision of the existing situation and future trajectory of tetraspecific antibodies.

1. Introduction To Tetraspecific Antibodies

1.1 Clinical Relevance
1.2 Historical Evolution

2. Tetraspecific Antibodies Mechanism Of Action

2.1 Multispecific Antibody Formats
2.2 Immune Synapse Formation & Target Engagement

3. Tetraspecific Antibodies Clinical Trials Overview

3.1 By Company
3.2 By Country
3.3 By Phase
3.4 By Indication

4. Tetraspecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase

4.1 Preclinical
4.2 Phase I
4.3 Phase I/II
4.4 Phase II

5. Current Clinical Development & Future Commercialization Outlook

5.1 Current Development Landscape
5.2 Future Commercialization Potential & Opportunities

6. Tetraspecific Antibodies Therapeutic Application By Indication

6.1 Cancer
- 6.1.1 Solid Tumors
- 6.1.2 Hematological Disorders
6.2 Autoimmune & Inflammatory Diseases

7. Tetraspecific Antibody Clinical Development Trend Analysis By Region

7.1 China
7.2 US
7.3 Europe

8. Tetraspecific Antibodies Proprietary Technologies By Company

8.1 Established Platforms
8.2 Emerging Platforms

9. Tetraspecific Antibodies Therapeutic Approaches

9.1 Monotherapy Use
9.2 Combination Therapy Strategies
9.3 Precision Targeting Applications

10. Competitive Landscape

10.1 Beijing StarMab Biomed Technology
10.2 Cellemedy
10.3 Innate Pharma
10.4 ModeX Therapeutics (OPKO Health)
10.5 Molecular Partners
10.6 OPKO Health
10.7 QLSF Biotherapeutics
10.8 Sichuan Baili Pharmaceutical
10.9 SystImmune

简介目录图表

List of Figures

Figure 1-1: FL518 - Structure
Figure 1-2: CRTB6 - Structure
Figure 1-3: LegoBody Tetraspecific Antibody Structure
Figure 1-4: LegoBody Tetra-N-Fab Post Thrombin Cleavage
Figure 2-1: Tetraspecific Antibody Structure
Figure 2-2: Tetraspecific Antibody Bringing T Cells & NK Cells In Close Proximity
Figure 3-1: Global - Tetraspecific Antibodies Clinical Trials By Company (Number Of Antibodies), 2025
Figure 3-2: Global - Tetraspecific Antibodies Clinical Trials By Company (Number Of Trials), 2025
Figure 3-3: Global - Tetraspecific Antibodies Clinical Trials By Phase (Number Of Antibodies), 2025
Figure 3-4: Global - Tetraspecific Antibodies Clinical Trials By Indication (Number Of Trials), 2025
Figure 5-1: Global Tetraspecific Antibody Market - Future Opportunities
Figure 6-1: GNC-039-101 Phase I Study (NCT04794972) - Initiation & Completion Year
Figure 6-2: GNC-035-103 Phase I Study (NCT05160545) - Initiation & Completion Year
Figure 6-3: MDX-2001-101 Phase I/II Study (NCT06239194) - Initiation & Completion Year
Figure 6-4: GNC-038-105 Phase I/II (NCT05627856) Study - Initiation & Completion Year
Figure 6-5: GNC-038 Phase I/II Study (NCT05485753) - Initiation & Completion Years
Figure 6-6: GNC-035-104 Phase I/II (NCT06066203) Study - Initiation & Completion Years
Figure 6-7: GNC-035-105 Phase I/II (NCT05944978) Study - Initiation & Completion Years
Figure 6-8: GNC-035-101 Phase I/II (NCT05104775) Study - Initiation & Completion Years
Figure 6-9: MP0533-CP101 Phase I/II (NCT05673057) Study - Initiation & Completion Year
Figure 6-10: IPH6501-101 Phase I/II (NCT06088654) Study - Initiation & Completion Year
Figure 6-11: GNC-038-106 Phase I (NCT06857214) Study - Initiation & Completion Year
Figure 6-12: GNC-039 Phase I Study (NCT04794972) - Initiation & Completion Year
Figure 7-1: Sichuan Biokin Pharmaceutical - Clinical Pipeline
Figure 7-2: ModeX Therapeutics - Pipeline
Figure 7-3: Mechanism of Action - IPH6501 vs. MP0533
Figure 8-1: DARPin Platform - Molecular Partners
Figure 8-2: ANKET(R) Platform - Innate Pharma
Figure 8-3: GNC Antibodies - Sichuan Baili Pharmaceutical/SystImmune
Figure 8-4: STEALTH - ModeX Therapeutics
Figure 8-5: MSTAR - ModeX Therapeutics
Figure 8-6: MSTAR - Salient Features
Figure 8-7: TECAD - QLSF Biotherapeutics
Figure 8-8: Multispecific VHH Antibody Drug Platform - Beijing StarMab Biomed Technology
Figure 8-9: MATCH - Numab
Figure 8-10: BiXAb - Features
Figure 8-11: Zybody - Zyngenia
Figure 8-12: T-sphaera - Cutting-Edge Plug-and-Play Platform for Drug Development
Figure 9-1: Tetraspecific Antibody GNC035 Targeting Cell Surface Antigen CD3
Figure 9-2: Tetraspecific Antibody Engaging CD3 T cells
Figure 9-3: Tetraspecific Antibody GNC039 Targeting Co-Stimulatory Receptor 4-1BB
Figure 9-4: IPH6501 - Tetraspecific NK Cell Engager
Figure 9-5: Tetraspecific Antibody GNC038 Targeting Immune Checkpoint Inhibitor PDL-1
Figure 9-6: Regulation of CD47 Signal From Cancer Cells By Tetraspecific Antibody
Figure 9-7: Novel Tetraspecific Format Developed By The Roche Pharma Research & Early Development

List of Tables

Table 6-1: Hematological Cancers - Ongoing Clinical Trial For GNC-038
Table 7-1: China - Ongoing Tetraspecific Antibody Clinical Trials
Table 9-1: Monotherapy Clinical Trials For Tetraspecific Antibodies

02-2729-4219

+886-2-2729-4219

License/价格

全球四重特异性抗体的临床试验，专利技术，治疗方法，市场机会的洞察(2025年)

Global Tetraspecific Antibodies Clinical Trials, Proprietary Technologies, Therapeutic Approaches & Market Opportunity Insight 2025

目录

第1章四重特异性抗体的简介

第2章四重特异性抗体的作用机制

第3章四重特异性抗体的临床试验概要

第4章四重特异性抗体的临床试验:企业，国家，适应症，各相

第5章目前临床开发与未来的商业化的展望

第6章四重特异性抗体的各适应症治疗应用

第7章四重特异性抗体临床开发趋势分析，各地区

第8章四重特异性抗体的企业独家技术

第9章利用四重特异性抗体的治疗方法

第10章竞争情形

Table of Contents